非酒精性脂肪性肝病、代谢相关脂肪性肝病与心血管疾病关联的国内外研究进展

doi:10.12114/j.issn.1007-9572.2023.0084

中国全科医学 ›› 2024, Vol. 27 ›› Issue (16): 2033-2038.DOI: 10.12114/j.issn.1007-9572.2023.0084

所属专题：心血管最新文章合集

非酒精性脂肪性肝病、代谢相关脂肪性肝病与心血管疾病关联的国内外研究进展

倪雪桐¹, 王若羲¹, 张晶², 杨兴华¹^,^*()

1．100069　北京市，首都医科大学公共卫生学院　临床流行病学北京市重点实验室
2．100069　北京市，首都医科大学附属北京佑安医院肝病中心三科

收稿日期:2023-08-07 修回日期:2023-10-24 出版日期:2024-06-05 发布日期:2024-04-08
通讯作者: 杨兴华
作者贡献：
倪雪桐负责论文整体写作构思、制定检索策略、收集与整理文献、撰写论文和论文修订；王若羲负责文献搜集与整理；张晶负责文章的修订与质量控制；杨兴华负责论文的修订、文章的质量控制及审校。
基金资助:
北京市自然科学基金资助项目(7202010)

Research Progress in the Correlation of Non-alcoholic Fatty Liver Disease and Metabolic-associated Fatty Liver Disease with Cardiovascular Diseases in China and Abroad

NI Xuetong¹, WANG Ruoxi¹, ZHANG Jing², YANG Xinghua¹^,^*()

1. School of Public Health, Capital Medical University/Beijing Key Laboratory of Clinical Epidemiology, Beijing 100069, China
2. Department Ⅲ, Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China

Received:2023-08-07 Revised:2023-10-24 Published:2024-06-05 Online:2024-04-08
Contact: YANG Xinghua

分享到

摘要/Abstract

摘要： 非酒精性脂肪性肝病（NAFLD）是目前全球最常见的慢性肝病，近年来大量研究证明其与代谢障碍密切相关，专家小组提出将其更名为代谢相关脂肪性肝病（MAFLD）。NAFLD/MAFLD不仅可能导致肝脏相关疾病的发病率和死亡率增加，也与心血管疾病的发病和死亡相关。本文对NAFLD/MAFLD的诊断标准进行比较，并总结了NAFLD/MAFLD与心血管疾病的关联性研究进展。结果表明，NAFLD/MAFLD与心血管疾病发病率增加均存在显著相关性，是心血管疾病的影响因素，且MAFLD患者心血管疾病发病风险高于NAFLD患者。本文为临床医生提供了对NAFLD/MAFLD患者进行心血管疾病风险评估和管理的依据，提示临床医生在处理NAFLD/MAFLD患者时，除了关注肝脏疾病的治疗外，还应重视患心血管疾病的风险。

关键词: 非酒精性脂肪性肝病, 代谢相关脂肪性肝病, 心血管疾病, 关联性研究, 综述

Abstract:

Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease worldwide, its close correlation with metabolic disorders has been demonstrated in numerous studies in recent years and an expert panel has proposed renaming it metabolic-associated fatty liver disease (MAFLD). NAFLD/MAFLD may not only increase the incidence and mortality of liver-related diseases but also relate to the incidence and mortality of cardiovascular diseases. This article compares the diagnostic criteria of NAFLD/MAFLD and reviews the research progress in the correlation of non-alcoholic fatty liver disease and metabolic-associated fatty liver disease with cardiovascular diseases. The results show that both NAFLD/MAFLD are significantly associated with the increased incidence of cardiovascular diseases and independent risk factors for cardiovascular diseases. Furthermore, MAFLD patients have a higher risk of developing cardiovascular diseases than NAFLD patients. This article provides clinical physicians with the basis for cardiovascular risk assessment and management in NAFLD/MAFLD patients, emphasizing that in addition to the treatment of liver disease, clinical physicians should also focus on the risk of cardiovascular disease in NAFLD/MAFLD patients.

Key words: Non-alcoholic fatty liver disease, Metabolic associated fatty liver disease, Cardiovascular diseases, Association study, Review

中图分类号:

R 575.5 R 54

倪雪桐,王若羲,张晶,等. 非酒精性脂肪性肝病、代谢相关脂肪性肝病与心血管疾病关联的国内外研究进展[J]. 中国全科医学, 2024, 27(16): 2033-2038. DOI: 10.12114/j.issn.1007-9572.2023.0084.
NI Xuetong,WANG Ruoxi,ZHANG Jing, et al. Research Progress in the Correlation of Non-alcoholic Fatty Liver Disease and Metabolic-associated Fatty Liver Disease with Cardiovascular Diseases in China and Abroad[J]. Chinese General Practice, 2024, 27(16): 2033-2038. DOI: 10.12114/j.issn.1007-9572.2023.0084.

参考文献 47

[1]	郭亮，汤其群. 非酒精性脂肪肝发病机制和治疗的研究进展[J]. 生命科学，2018，30(11):1165-1172. DOI：10.13376/j.cbls/2018141.
[2]	MANTOVANI A, SCORLETTI E, MOSCA A, et al. Complications，morbidity and mortality of nonalcoholic fatty liver disease[J]. Metabolism，2020，111S:154170. DOI：10.1016/j.metabol.2020.154170.
[3]	ESLAM M, NEWSOME P N, SARIN S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease：an international expert consensus statement[J]. J Hepatol，2020，73(1):202-209. DOI：10.1016/j.jhep.2020.03.039.
[4]	NAN Y M, AN J H, BAO J F, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol，2021，75(2):454-461. DOI：10.1016/j.jhep.2021.05.003.
[5]	蔡联英，王文娟，梁运啸，等. 代谢相关脂肪性肝病与代谢综合征相关性的研究进展[J]. 中国临床新医学，2021，14(7):730-734. DOI：10.3969/j.issn.1674-3806.2021.07.22.
[6]	吴婉雯，李晓伟，崔立红. 脂肪肝诊断标准的变更对心血管疾病风险分层管理的价值分析[J]. 解放军医学杂志，2021，46(5):486-491. DOI：10.11855/j.issn.0577-7402.2021.05.10.
[7]	LIU S S, WANG J L, WU S J, et al. The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis：a prospective analysis[J]. Metabolism，2021，120:154779. DOI：10.1016/j.metabol.2021.154779.
[8]	MÉNDEZ-SÁNCHEZ N, DÍAZ-OROZCO L, CÓRDOVA-GALLARDO J. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness：Mexican experience[J]. J Hepatol，2021，75(1):221-222. DOI：10.1016/j.jhep.2021.04.021.
[9]	CHALASANI N, YOUNOSSI Z, LAVINE J E, et al. The diagnosis and management of nonalcoholic fatty liver disease：practice guidance from the American Association for the Study of Liver Diseases[J]. Hepatology，2018，67(1):328-357. DOI：10.1002/hep.29367.
[10]	COTTER T G, RINELLA M. Nonalcoholic fatty liver disease 2020：the state of the disease[J]. Gastroenterology，2020，158(7):1851-1864. DOI：10.1053/j.gastro.2020.01.052.
[11]	中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南（2018年更新版）[J]. 临床肝胆病杂志，2018，34(5):947-957. DOI：10.3969/j.issn.1001-5256.2018.05.007.
[12]	CAUSSY C, AUBIN A, LOOMBA R. The relationship between type 2 diabetes，NAFLD，and cardiovascular risk[J]. Curr Diab Rep，2021，21(5):15. DOI：10.1007/s11892-021-01383-7.
[13]	KASPER P, MARTIN A, LANG S, et al. NAFLD and cardiovascular diseases：a clinical review[J]. Clin Res Cardiol，2021，110(7):921-937. DOI：10.1007/s00392-020-01709-7.
[14]	HENSON J B, SIMON T G, KAPLAN A, et al. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease[J]. Aliment Pharmacol Ther，2020，51(7):728-736. DOI：10.1111/apt.15660.
[15]	BARATTA F, PASTORI D, ANGELICO F, et al. Nonalcoholic fatty liver disease and fibrosis associated With increased risk of cardiovascular Events in a prospective study[J]. Clin Gastroenterol Hepatol，2020，18(10):2324-2331.e4. DOI：10.1016/j.cgh.2019.12.026.
[16]	ALLEN A M, THERNEAU T M, LARSON J J, et al. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death：a 20 year-community study[J]. Hepatology，2018，67(5):1726-1736. DOI：10.1002/hep.29546.
[17]	TARGHER G, BYRNE C D, LONARDO A, et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease：a meta-analysis[J]. J Hepatol，2016，65(3):589-600. DOI：10.1016/j.jhep.2016.05.013.
[18]	CARUSO M G, VERONESE N, NOTARNICOLA M, et al. Fatty liver and mortality：a cohort population study in South Italy[J]. BMJ Open，2019，9(6):e027379. DOI：10.1136/bmjopen-2018-027379.
[19]	KIM D, KIM W R, KIM H J, et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States[J]. Hepatology，2013，57(4):1357-1365. DOI：10.1002/hep.26156.
[20]	SIMON T G, ROELSTRAETE B, KHALILI H, et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease：results from a nationwide cohort[J]. Gut，2021，70(7):1375-1382. DOI：10.1136/gutjnl-2020-322786.
[21]	ANENI E C, ONI E T, MARTIN S S, et al. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk[J]. J Hypertens，2015，33(6):1207-1214. DOI：10.1097/HJH.0000000000000532.
[22]	RYOO J H, SUH Y J, SHIN H C, et al. Clinical association between non-alcoholic fatty liver disease and the development of hypertension[J]. J Gastroenterol Hepatol，2014，29(11):1926-1931. DOI：10.1111/jgh.12643.
[23]	LATEA L, NEGREA S, BOLBOACA S. Primary non-alcoholic fatty liver disease in hypertensive patients[J]. Australas Med J，2013，6(6):325-330. DOI：10.4066/AMJ.2013.1648.
[24]	GAGGINI M, MORELLI M, BUZZIGOLI E, et al. Non-alcoholic fatty liver disease （NAFLD） and its connection with insulin resistance，dyslipidemia，atherosclerosis and coronary heart disease[J]. Nutrients，2013，5(5):1544-1560. DOI：10.3390/nu5051544.
[25]	CHUNG G E, CHOI S Y, KIM D, et al. Nonalcoholic fatty liver disease as a risk factor of arterial stiffness measured by the cardioankle vascular index[J]. Medicine，2015，94(12):e654. DOI：10.1097/MD.0000000000000654.
[26]	LIU Z P, WEI R F, LI Y. Coronary heart disease is associated with nonalcoholic fatty liver disease in patients without hypertension and diabetes[J]. Medicine，2020，99(26):e20898. DOI：10.1097/MD.0000000000020898.
[27]	ANSTEE Q M, MANTOVANI A, TILG H, et al. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol，2018，15(7):425-439. DOI：10.1038/s41575-018-0010-0.
[28]	屠燕，杨婵娟，黄莹，等. 非酒精性脂肪肝与心血管疾病相关性的研究[J]. 自然杂志，2022，44(2):149-154. DOI：10.3969/j.issn.0253-9608.2022.02.008.
[29]	DONNELLAN E, COTTER T G, WAZNI O M, et al. Impact of nonalcoholic fatty liver disease on arrhythmia recurrence following atrial fibrillation ablation[J]. JACC Clin Electrophysiol，2020，6(10):1278-1287. DOI：10.1016/j.jacep.2020.05.023.
[30]	WEN W, LI H, WANG C Y, et al. Metabolic dysfunction-associated fatty liver disease and cardiovascular disease：a meta-analysis[J]. Front Endocrinol，2022，13:934225. DOI：10.3389/fendo.2022.934225.
[31]	LIANG Y B, CHEN H L, LIU Y X, et al. Association of MAFLD with diabetes，chronic kidney disease，and cardiovascular disease：a 4.6-year cohort study in China[J]. J Clin Endocrinol Metab，2022，107(1):88-97. DOI：10.1210/clinem/dgab641.
[32]	GUERREIRO G T S, LONGO L, FONSECA M A, et al. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?[J]. Hepatol Int，2021，15(2):380-391. DOI：10.1007/s12072-021-10157-y.
[33]	LEE H, LEE Y H, KIM S U, et al. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk：a nationwide cohort study[J]. Clin Gastroenterol Hepatol，2021，19(10):2138-2147.e10. DOI：10.1016/j.cgh.2020.12.022.
[34]	YONEDA M, YAMAMOTO T, HONDA Y, et al. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view：a retrospective nationwide claims database study in Japan[J]. J Gastroenterol，2021，56(11):1022-1032. DOI：10.1007/s00535-021-01828-6.
[35]	MOON J H, KIM W, KOO B K, et al. Metabolic dysfunction-associated fatty liver disease predicts long-term mortality and cardiovascular disease[J]. Gut Liver，2022，16(3):433-442. DOI：10.5009/gnl210167.
[36]	KIM D, KONYN P, SANDHU K K, et al. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States[J]. J Hepatol，2021，75(6):1284-1291. DOI：10.1016/j.jhep.2021.07.035.
[37]	缪茜. NAFLD及MAFLD患者主要心血管病发病风险及预测研究[D]. 兰州：兰州大学，2022.
[38]	ISMAIEL A, SPINU M, SOCACIU C, et al. Metabolic biomarkers related to cardiac dysfunction in metabolic-dysfunction-associated fatty liver disease：a cross-sectional analysis[J]. Nutr Diabetes，2022，12(1):4. DOI：10.1038/s41387-022-00182-7.
[39]	GUTIÉRREZ-CUEVAS J, SANTOS A, ARMENDARIZ-BORUNDA J. Pathophysiological molecular mechanisms of obesity：a link between MAFLD and NASH with cardiovascular diseases[J]. Int J Mol Sci，2021，22(21):11629. DOI：10.3390/ijms222111629.
[40]	WONG C R, LIM J K. The association between nonalcoholic fatty liver disease and cardiovascular disease outcomes[J]. Clin Liver Dis，2018，12(2):39-44. DOI：10.1002/cld.721.
[41]	DUELL P B, WELTY F K, MILLER M, et al. Nonalcoholic fatty liver disease and cardiovascular risk：a scientific statement from the American heart association[J]. Arterioscler Thromb Vasc Biol，2022，42(6):e168-185. DOI：10.1161/ATV.0000000000000153.
[42]	GALIERO R, CATURANO A, VETRANO E, et al. Pathophysiological mechanisms and clinical evidence of relationship between Nonalcoholic fatty liver disease （NAFLD） and cardiovascular disease[J]. Rev Cardiovasc Med，2021，22(3):755-768. DOI：10.31083/j.rcm2203082.
[43]	DEPRINCE A, HAAS J T, STAELS B. Dysregulated lipid metabolism links NAFLD to cardiovascular disease[J]. Mol Metab，2020，42:101092. DOI：10.1016/j.molmet.2020.101092.
[44]	JIANG F J, CHEN Q, WANG W, et al. Hepatocyte-derived extracellular vesicles promote endothelial inflammation and atherogenesis via microRNA-1[J]. J Hepatol，2020，72(1):156-166. DOI：10.1016/j.jhep.2019.09.014.
[45]	TARANTINO G. NAFLD or MAFLD：that is the conundrum[J]. Hepatobiliary Pancreat Dis Int，2022，21(2):103-105. DOI：10.1016/j.hbpd.2022.01.008.
[46]	DUFOUR J F. Time to abandon NASH?[J]. Hepatology，2016，63(1):9-10. DOI：10.1002/hep.28276.
[47]	ROMERO-GÓMEZ M, ZELBER-SAGI S, TRENELL M. Treatment of NAFLD with diet，physical activity and exercise[J]. J Hepatol，2017，67(4):829-846. DOI：10.1016/j.jhep.2017.05.016.

非酒精性脂肪性肝病、代谢相关脂肪性肝病与心血管疾病关联的国内外研究进展

Research Progress in the Correlation of Non-alcoholic Fatty Liver Disease and Metabolic-associated Fatty Liver Disease with Cardiovascular Diseases in China and Abroad

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 47

相关文章 15

编辑推荐

Metrics

留言

[1]	倪嘉淳, 蔡增进, 侯长城, 江琼, 康健, 杨向东, 樊文彬. 痔病评估分类法研究进展及评估价值分析[J]. 中国全科医学, 2024, 27(20): 2545-2550.
[2]	侯娜娜, 冯金章, 刘锁红, 冯俊芳, 薛小艳, 尹娜, 迟戈夫. 血尿酸/肌酐比值与代谢相关脂肪性肝病的相关性研究[J]. 中国全科医学, 2024, 27(20): 2476-2482.
[3]	中国血脂管理指南修订联合专家委员会. 中国血脂管理指南（基层版2024年）[J]. 中国全科医学, 2024, 27(20): 2429-2436.
[4]	李孟野, 姜一农. 可溶性肾素前体受体在多系统疾病中的研究进展[J]. 中国全科医学, 2024, 27(18): 2295-2300.
[5]	康殷楠, 石嘉琪, 王俊科, 李斌, 李初谊, 马俊, 于晓辉. 抗体药物偶联物在人表皮生长因子受体2低表达胃癌中的应用研究进展[J]. 中国全科医学, 2024, 27(18): 2287-2294.
[6]	苗立鹏, 任柯好, 李梦蝶, 吕军城. 2009—2021年中国心血管疾病死亡趋势分析与预测研究[J]. 中国全科医学, 2024, 27(18): 2260-2264.
[7]	薛亚男, 欧敏行, 张秀杰, 孟庆雪, 刘莹. 《2023 AHA/ACC/ACCP/ASPC/NLA/PCNA慢性冠状动脉疾病患者管理指南》要点解读[J]. 中国全科医学, 2024, 27(18): 2173-2178.
[8]	杨旭, 姚弥. 美国预防临床服务指南工作组《无心血管疾病危险因素成年人预防心血管疾病的健康饮食和身体活动：行为咨询干预推荐声明》解读[J]. 中国全科医学, 2024, 27(17): 2064-2069.
[9]	胥梓薇, 程康耀, 桂莉. 突发重大传染病事件背景下过负荷医院管理研究的范围综述[J]. 中国全科医学, 2024, 27(16): 2039-2044.
[10]	吴美倩, 肖进, 李斐斐, 胡镕镕, 刘彩霞. 24小时活动行为：老年人健康影响因素研究的新方向[J]. 中国全科医学, 2024, 27(15): 1911-1916.
[11]	王芳芳, 朱莉, 幸佳佳, 庞日朝, 苟翔, 张安仁. 创伤性中枢神经系统损伤后肠道屏障变化及其可能机制的研究进展[J]. 中国全科医学, 2024, 27(14): 1775-1781.
[12]	曹佳岑, 张宏坤, 赵文, 南月敏, 李冬冬. 血红素氧合酶1调节铁死亡在非酒精性脂肪性肝病中的研究进展[J]. 中国全科医学, 2024, 27(14): 1782-1788.
[13]	杜书琴, 钱立锋, 熊烈, 史汉强, 石彦波. 铁死亡：抑郁症治疗的新靶点[J]. 中国全科医学, 2024, 27(12): 1417-1423.
[14]	冉东升, 逯艳艳, 辛春玲, 马颖才. 血脂异常与结直肠锯齿状病变、结直肠癌相关性研究进展[J]. 中国全科医学, 2024, 27(12): 1424-1430.
[15]	张娜文, 黄少敏, 田利民. 成人血清骨钙素水平与非酒精性脂肪性肝病发生风险的Meta分析[J]. 中国全科医学, 2024, 27(12): 1519-1524.